Post hoc analysis of STRONG-HF trial underscores benefits of higher guideline-directed medical therapy doses in acute heart failure, showing lower rates of death or readmission at 6 months,
Anuradha Lala-Trindade, MD, shares approaches to personalizing quadruple therapy for people with heart failure, focusing on family history, device-based therapies, and optimizing therapy early.